Clinical Trial

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Study acronym: START
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-04-19; most recent amendment 2024-12-17.
Status change: Not Yet Recruiting → Recruiting 2023-08-21
Trial Details
NCT Number NCT05345327
Lead Sponsor The George Institute
Collaborators: The University of New South Wales, Monash University, University of Sydney
Conditions Type 2 Diabetes
Enrollment 994 participants
Start Date 2023-01-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-20